Vivos Therapeutics, Inc., a company operating within the Health Care sector, has recently announced its intention to submit a registration statement to the U.S. Securities and Exchange Commission (SEC) for a proposed rights offering. This announcement, made on June 16, 2026, marks a significant development for the company, which is publicly traded on the Nasdaq stock exchange and specializes in medical technology for treating sleep disordered breathing and obstructive sleep apnea.
The proposed rights offering is designed to distribute subscription rights to shareholders as a dividend, contingent upon the registration statement becoming effective. The record date for this offering is expected to be set 30 days after the registration statement’s effectiveness. Each subscription right will allow shareholders to purchase one share at an exercise price determined by the greater of a fixed amount or a percentage above the prior-record-date market price. The rights will be exercisable for a period of nine months, during which holders may receive a subsequent right with a higher exercise price and similar terms.
This strategic move by Vivos Therapeutics comes at a time when the company is navigating a challenging financial landscape. As of June 16, 2026, the company’s close price stood at $0.5112, a stark contrast to its 52-week high of $7.95 recorded on July 10, 2025. The current market capitalization of $7,570,000 reflects the volatility and uncertainty faced by the company in recent months. Furthermore, the negative price-to-earnings ratio of -0.25 underscores the financial hurdles that Vivos Therapeutics must overcome to achieve sustainable growth.
The proposed rights offering is contingent upon several factors, including SEC approval, compliance with exchange and shareholder-approval requirements, availability of unissued shares, board approval, and prevailing market conditions. The company has explicitly stated that there is no assurance the offering will be completed and reserves the right to modify or cancel the proposal before completion.
Vivos Therapeutics’ mission to revolutionize the treatment of sleep-related respiratory disorders remains at the forefront of its strategic objectives. By providing innovative solutions aimed at improving patients’ quality of life, the company seeks to establish itself as a leader in the medical technology sector. However, the success of its financial strategies, including the proposed rights offering, will be crucial in determining its ability to achieve these goals.
As Vivos Therapeutics navigates these complex financial and regulatory landscapes, stakeholders will be closely monitoring the company’s progress. The outcome of the proposed rights offering could significantly impact the company’s financial stability and its capacity to continue its mission of transforming the treatment landscape for sleep disordered breathing and obstructive sleep apnea.
